Residual tumor doesn't affect survival in neuroblastoma
Topic overview
Retrospective study of 131 non-high-risk neuroblastoma patients found that gross residual tumor after chemotherapy does not predict worse progression-free or overall survival. Adjuvant radiation and isotretinoin showed no benefit for residual disease, suggesting GRT may not require additional treatment in this population.
Key takeaways
- Gross residual tumor >1 cm³ after chemotherapy does not predict worse survival in non-high-risk neuroblastoma patients.
- Adjuvant radiation and isotretinoin therapy showed no survival benefit for patients with residual tumor after chemotherapy.
- Degree of tumor volume reduction during treatment is more prognostically significant than absolute residual tumor size.
- Adjuvant therapy should be reserved for patients with poor treatment response, not routinely given for residual tumor presence.
Comments